Bovine Patents (Class 800/15)
-
Patent number: 7307198Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: November 21, 2001Date of Patent: December 11, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7304204Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: November 21, 2001Date of Patent: December 4, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7238851Abstract: The present invention features compositions (e.g, nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulations including that nucleic acid or biologically active variants thereof) and methods that can be used to effectively modify the content of PUFAs in animal cells (i.e., cells other than those of C. elegants, for example, mammalian cells such as myocytes, neurons (whether of the periferal or central nervous system), adipocytes, endothelial cells, and cancer cells). The modified cells, whether in vivo or ex vivo (e.g., in tissue culture), transgenic animals containing them, and food products obtained from those animals (e.g., meat or other edible parts of the animals (e.g., liver, kidney, or sweetbreads)) are also within the scope of the present invention.Type: GrantFiled: March 12, 2002Date of Patent: July 3, 2007Assignee: The General Hospital CorporationInventor: Jing X. Kang
-
Patent number: 7232938Abstract: A method of reconstituting an animal embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more animals. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 11, 2004Date of Patent: June 19, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7199281Abstract: The present invention provides methods of producing transgenic livestock animals. The methods generally involve first introducing a nucleoprotein made up of nucleic acid and a recombinase into a totipotent or pluripotent cell to produce a recombinant totipotent or pluripotent cell and then growing the recombinant totipotent or pluripotent cell to produce the transgenic livestock animal. The invention further provides kits for use in generating transgenic non-human animals of the invention.Type: GrantFiled: September 6, 2002Date of Patent: April 3, 2007Assignee: The Regents of the University of CaliforniaInventors: James D. Murray, Elizabeth A. Maga, Gary B. Anderson, Stefanie M. Oppenheim
-
Patent number: 7169963Abstract: The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality.Type: GrantFiled: September 30, 2003Date of Patent: January 30, 2007Assignee: Board of Trustees of the University of IllinoisInventors: Matthew B. Wheeler, Sharon M. Donovan, Gregory T. Bleck, Marcia Monaco-Siegel
-
Patent number: 7157615Abstract: Disclosed is a method for the recombinant production of biofilaments, such as spider silk or insect fibroins, using transgenic animals which secrete the biofilaments in their milk and/or urine, and transgenic cells which secrete the biofilaments into culture media. Such a method is useful for producing large quantities of biofilament material. Also disclosed is a nucleic acid molecule for generating such transgenic animals.Type: GrantFiled: March 17, 1998Date of Patent: January 2, 2007Assignee: Nexia Biotechnologies, Inc.Inventors: Costas N. Karatzas, Jeffrey D. Turner, Anthoula Lazaris-Karatzas
-
Patent number: 7157616Abstract: The invention is based on the discovery that certain variants of ?-casein may induce Type-1 diabetes in susceptible individuals while other variants do not. The invention consists of the selection of non-diabetogenic milk producing cows and recovering and processing their milk and milk products. Another aspect of the invention is selectively breeding cows which produce the non-diabetogenic milk.Type: GrantFiled: July 25, 2002Date of Patent: January 2, 2007Inventors: Robert B Elliott, Jeremy P Hill
-
Patent number: 7074983Abstract: The present invention relates to the production of a transgenic bovine which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.Type: GrantFiled: November 16, 2001Date of Patent: July 11, 2006Assignees: Kirin Beer Kabushiki Kaisha, Hematech, LLCInventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne
-
Patent number: 7067713Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.Type: GrantFiled: January 31, 2001Date of Patent: June 27, 2006Assignee: Pharming Intellectual Property B.V.Inventors: Jan Henricus Nuijens, Henricus Antonius Van Veen, Frank Robert Pieper, Joris Jan Heus
-
Patent number: 7045677Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.Type: GrantFiled: December 21, 2001Date of Patent: May 16, 2006Assignee: Pharming Intellectual Property BVInventors: Ian Robert Cottingham, Graham Edward McCreath
-
Patent number: 7041870Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: November 30, 2001Date of Patent: May 9, 2006Assignees: Medarex, Inc., Kirin Brewery Company LimitedInventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Patent number: 7030289Abstract: The present invention relates to the stabilization of milk from transgenic animals. In particular, the invention relates to the protection of proteins (e.g. fibrinogen) expressed in milk from transgenic animals by co-expression of a serine proteinase inhibitor (e.g., ?1-antitrypsin) in the milk of the transgenic animals.Type: GrantFiled: May 18, 2001Date of Patent: April 18, 2006Assignee: PPL Therapeutics (Scotland) LtdInventors: Ian Robert Cottingham, Graham Edward McCreath
-
Patent number: 6987211Abstract: The present invention relates to novel alternative forms of human acetylcholinesterase (AChE) and nucleotide sequences encoding the same. The genes encoding the novel forms of human AChE have been identified in various malignant tumor cells. In a further aspect, the invention relates to a transgenic animal assay system for evaluating efficacy of drugs against cholinergic proteins, prior to or in the course of therapeutic treatment. Transgenic animals, preferably developing tadpole of Xenopus or mice which express human AChE, are used. The transgenic animal assay system is also useful for evaluating the toxicity of substances which potentially block human AChE (e.g. organophosphorous compounds).Type: GrantFiled: May 12, 1999Date of Patent: January 17, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Hermona Soreq, Haim Zakut, Moshe Shani
-
Patent number: 6984772Abstract: A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glands of the animals and secreting the expressed product into a body fluid. Methodology employing such a mammal yields recombinant physiologically functional fibrinogens, subunit chain polypeptides thereof, and modified or fusion fibrinogens.Type: GrantFiled: May 17, 1995Date of Patent: January 10, 2006Assignees: Virginia Tech Intellectual Properties, Inc., American Red Cross, The University of North Carolina at Chapel HillInventors: William H. Velander, William N. Drohan, Henryk Lubon, John L. Johnson
-
Patent number: 6924412Abstract: Methods and processes for raising the concentration of a first class of immunoglobulin relative to at least a second class of immunoglobulin in a compartment of the body of a non-human animal or the progeny thereof, as well as the animals produced by such methods and processes. Such methods and processes provide for the collection of antibodies produced by mucosal surfaces of the animal. Preferably, the production is in the mammary gland. Antibodies can be collected from the milk of the animal. Antibodies may be used for medical and/or nutritional purposes.Type: GrantFiled: July 21, 2000Date of Patent: August 2, 2005Assignee: Arriwan Holding B.V.Inventors: Nanda de Groot, Herman Albert de Boer
-
Patent number: 6906238Abstract: The present invention provides methods of producing a cloned non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing donor genetic material into a metaphase I oocyte; introducing donor genetic material into a non-enucleated oocyte; introducing donor genetic material obtained from a donor cell that is at metaphase into an oocyte; introducing donor genetic material into an oocyte, and naturally activating the oocyte or the NT embryo; and introducing donor genetic material obtained from a donor cell that is at late G1 phase into an oocyte.Type: GrantFiled: March 15, 2001Date of Patent: June 14, 2005Assignee: University of Georgia Research Foundation, Inc.Inventor: Steven Stice
-
Patent number: 6891082Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.Type: GrantFiled: April 24, 2001Date of Patent: May 10, 2005Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Patent number: 6888047Abstract: The invention relates to recombinant DNA constructs, a method for producing a recombinant biologically active protein in vivo in the urine of a non-human mammal using a kidney-specific promoter, such as the uromodulin promoter, and the transgenic non-human mammals that serve as urine-based bioreactors for protein production.Type: GrantFiled: June 26, 2000Date of Patent: May 3, 2005Assignee: New York UniversityInventors: Xue-Ru Wu, Tung-Tien Sun
-
Patent number: 6872868Abstract: Genetic transformation of a zygote and the embryo and mature organism which result therefrom is obtained by placing or inserting exogenous genetic material into the nucleus of the zygote or into any genetic material which ultimately forms at least a part of the nucleus of the zygote. It is preferred that the exogenous genetic material be added to a pronuclei of the zygote and is particularly preferred that it be added to the male pronucleus of the zygote. Thereafter, the zygote is allowed to undergo differentiation and development into the organism. The genotype of the zygote and the organism which results therefrom will include the genotype of the exogenous genetic material and the exogenous genetic material will be phenotypically expressed. The invention can be utilized in a variety of ways including, for example, animal and plant breeding to modify or create new species, it can be used in epigenetics and in the understanding and treatment of genetic diseases.Type: GrantFiled: May 24, 1995Date of Patent: March 29, 2005Assignee: Ohio UniversityInventors: Thomas E. Wagner, Peter C. Hoppe
-
Publication number: 20040265820Abstract: This invention relates to a method of determining the susceptibility of a subject to prion disease comprising the steps of: (a) providing a sample from said subject and in determining the human leucocyte antigen specificity of said sample, wherein if said sample has DQ7 human leucocyte antigen specificity, this indicates that said subject has a decreased susceptibility to prion disease, and if said sample does not have DQ7 human leucocyte antigen specificity, this indicates that said subject has an increased susceptibility to prion disease.Type: ApplicationFiled: August 26, 2004Publication date: December 30, 2004Inventors: Graham S. Jackson, John Collinge
-
Publication number: 20040250305Abstract: The subject invention relates to a method of transferring a specific immune response into a cloned animal. In this manner, one may create a specific, selective, secondary immune response in an otherwise immunologically naïve animal.Type: ApplicationFiled: September 4, 2003Publication date: December 9, 2004Inventors: Zuhair A. Latif, Sean F. Nowlan
-
Publication number: 20040241723Abstract: The present invention provides for a direct correlation between milk production in livestock animals and the presence of alleles of a gene encoding an adipocyte-specific polypeptide, termed leptin, which gene is hereinafter referred to as ob. The invention also provides novel compositions consisting essentially of specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification, thus providing a rapid, sensitive and specific method for the detection of the ob-gene polymorphism which may be present in a specimen. The invention further provides for methods of screening bovine to determine those having predictably more milk productivity and advantageously selecting those livestock for future breeding and management purposes based on the ob polymorphisms.Type: ApplicationFiled: March 18, 2004Publication date: December 2, 2004Inventors: Foley Leigh Shaw Marquess, Bernard Laarveld, Fiona Cleverly Buchanan, Andrew Gerald Van Kessel, Sheila Marie Schmutz, Cheryl Waldner, David Christensen
-
Publication number: 20040231010Abstract: The present invention provides transgenic ungulates that include a transgene that encodes lysozyme, and further has an attenuated or non-functional &bgr;-lactoglobulin allele. The invention further provides methods for producing such animals. The invention further provides methods of producing a food product, such as milk, or a milk product, using a subject transgenic ungulate, as well as food products harvested from a subject transgenic ungulate.Type: ApplicationFiled: January 7, 2004Publication date: November 18, 2004Inventors: James D. Murray, Gary B. Anderson, Elizabeth A. Maga, Sushma Pati, David A. Zarling
-
Publication number: 20040199934Abstract: Transgenic rats are generated which incorporate a primate B1 bradykinin receptor transgene(s) into their genome. This B1 bradykinin receptor gene is expressed in these transgenic rats, which results in binding of compounds which are selective for the primate form (such as the human form) of the receptor and not the rat form of the receptor. Therefore, the expressed transgenes within these transgenic lines mimic antagonist and agonist selectivity of the wild type primate B1 bradykinin receptor. These transgenic animals are useful as a specific receptor occupancy model for modulators of the B1 bradykinin receptor from the human or closely related species, as well as providing for an animal model system for assessment of the pharmacodynamic properties of such a B1 bradykinin modulator(s).Type: ApplicationFiled: February 19, 2004Publication date: October 7, 2004Inventors: John W Hess, Robert I Gould, Douglas J Pettibone
-
Publication number: 20040180041Abstract: Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.Type: ApplicationFiled: March 25, 2004Publication date: September 16, 2004Applicant: University of MassachusettsInventors: Steven L. Stice, Jose Cibelli, James M. Robl
-
Publication number: 20040177394Abstract: The subject invention relates to a method of transferring a specific immune response into a cloned animal. In this manner, one may create a specific, selective, secondary immune response in an otherwise immunologically naïve animal.Type: ApplicationFiled: March 11, 2004Publication date: September 9, 2004Inventor: Zuhair A. Latif
-
Publication number: 20040177395Abstract: The subject invention relates to a method of creating a cloned animal having the precise immunological response and capabilities as the founder animal.Type: ApplicationFiled: March 11, 2004Publication date: September 9, 2004Inventor: Zuhair A. Latif
-
Publication number: 20040154048Abstract: Methods for the activation of nuclear transferred embryos using elevated calcium levels introduced into cells, and a maturation promoting factor (MPF) inhibitor are described. Elevated calcium levels introduced into the embryo cells from a culture medium containing elevated calcium levels, in the range 2 mM to about 12 mM, followed directly and immediately by incubation with DMAP are described. Also described are animals produced from embryos so treated.Type: ApplicationFiled: March 22, 2004Publication date: August 5, 2004Inventors: Christopher Gerald Grupen, Mark Brenton Nottle
-
Publication number: 20040154045Abstract: Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens.Type: ApplicationFiled: November 6, 2003Publication date: August 5, 2004Inventor: Richard A. Berg
-
Publication number: 20040133930Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human FIX protein without the benefit of the presence of a complete milk gene sequence for gene rescue, and a signal sequence is active in directing newly expressed Factor IX into the milk of the animal at levels in an unactivated form that is suitable for subsequent processing for therapeutic applications in treating Hemophilia B. The transgenic mammals are preferably pigs, cows, sheep, goats and rebbits. The application include milk derivatives for oral delivery and oral tolerization in the treatment of Hemophilia B.Type: ApplicationFiled: February 12, 2004Publication date: July 8, 2004Inventors: Julian D. Cooper, William Hugold Velander, Tanya K. O'Sickey
-
Patent number: 6743966Abstract: Production of proteins not normally secreted through conventional pathways such as membrane proteins including, for example, CFTR associated with cystic fibrosis, is now made possible by collection of such protein from the milk of lactating transgenic animals.Type: GrantFiled: June 27, 2002Date of Patent: June 1, 2004Assignee: Genzyme CorporationInventor: Alan E. Smith
-
Publication number: 20040098756Abstract: The present invention concerns transgenic vertebrates that are useful in expressing proteins and in producing antibodies. The present invention discloses methods for producing vertebrates that are transgenic for a bacteriophage RNA polymerase. The present invention further discloses methods for the use of such transgenic vertebrates in protein expression and in antibody production.Type: ApplicationFiled: October 29, 2003Publication date: May 20, 2004Inventor: Sujay Singh
-
Publication number: 20040093624Abstract: The present invention relates to a method of improving development potential of an embryo, embryos developed therefrom and organisms resulting from embryos developed from the method. In a first aspect of the present invention, there is provided a method of culturing an embryo to improve development potential, said method comprising; obtaining an embryo; and culturing the embryo to enhance trophectoderm development of the embryo. The method relates to improving the chances of an embryo implanting to result in a successful pregnancy. The embryos desirably become implantation competent favouring foetal-maternal interaction and development to term of an embryo. The trophectoderm stimulating agent may be any compound which is proven to stimulate normal trophectoderm development. Preferably the agent is fibroblast growth factor-4 (FGF4) protein.Type: ApplicationFiled: June 5, 2003Publication date: May 13, 2004Inventors: Andrew James French, Robert Daniels
-
Publication number: 20040088745Abstract: Disclosed are methods of genetically modifying animals such that the animals will produce offspring or progeny of a single sex.Type: ApplicationFiled: February 25, 2003Publication date: May 6, 2004Inventors: James Robl, F. Abel Ponce De Leon
-
Publication number: 20040088744Abstract: The present invention provides methods for the production of a transgenic bovine. In particular, the present invention provides methods for generating transgenic bovines with transgenes that enhance the ability of the bovines to metabolize lipids. The present invention thus provides bovines resistant to fatty liver disease. The compositions and methods of the present invention provide a solution to costly disease.Type: ApplicationFiled: September 22, 2003Publication date: May 6, 2004Inventors: Alan Attie, Gregory Bleck, Robert Bremel, Jane Homan
-
Patent number: 6727405Abstract: A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling secretion of the protein.Type: GrantFiled: May 19, 1994Date of Patent: April 27, 2004Assignee: Genzyme CorporationInventors: Katherine Gordon, Suzanne Groet, Lothar Hennighausen, Heiner Westphal
-
Publication number: 20040068760Abstract: The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.Type: ApplicationFiled: May 19, 2003Publication date: April 8, 2004Inventors: James M. Robl, Philippe Collas, Eddie Sullivan, P. Kasinathan, Richard A. Goldsby, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida
-
Publication number: 20040064843Abstract: A method is disclosed for improving the reliability of physical measurements obtained from array hybridization studies performed on an array having a large number of genomic samples including a replicate subset containing a small number of replicates insufficient for making precise and valid statistical inferences. An error in measurement of a sample is estimated by combining estimates obtained with individual samples in the replicate subset, and utilizing the estimated sample error as a standard for accepting or rejecting the measurement of a sample under test.Type: ApplicationFiled: July 24, 2003Publication date: April 1, 2004Inventors: Edward Susko, Robert Nadon
-
Publication number: 20040064841Abstract: The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality.Type: ApplicationFiled: September 30, 2003Publication date: April 1, 2004Applicant: Board of Trustees of the University of IllinoisInventors: Matthew B. Wheeler, Sharon M. Donovan, Gregory T. Bleck, Marcia Monaco-Seigel
-
Patent number: 6713662Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: GrantFiled: June 7, 1995Date of Patent: March 30, 2004Assignees: Pharming Intellectual Property B.V., Cohesion TechnologiesInventors: Costas N. Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul David Toman
-
Publication number: 20040055025Abstract: The present invention provides a method and materials for reproducing an immune response of a mammal against one or more antigens of interest. The method preferably involves cloning a founder mammal and producing an immune response in the clone that is substantially identical to the immune response of the founder animal to the antigen or antigens of interest. Accordingly, a source of valuable antibodies can be maintained despite the death or illness of the antibody producing animal.Type: ApplicationFiled: January 30, 2003Publication date: March 18, 2004Applicant: Infigen, Inc.Inventors: Erik J. Forsberg, Gregory H. Leno, Jeffrey Betthauser, Kenneth Eilertsen, Michael D. Bishop
-
Patent number: 6706947Abstract: The invention relates to an animal model of cancer. The animal carries a tumour xenograft and is immunosuppressed by administration of cyclosporin and ketoconazole. The model is useful for studying cancer and treatment thereof.Type: GrantFiled: September 30, 2002Date of Patent: March 16, 2004Assignee: Fremantle HospitalInventor: John Harvey Turner
-
Publication number: 20040019920Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: ApplicationFiled: March 11, 2003Publication date: January 29, 2004Applicant: Gala Design, Inc.Inventors: Robert D. Bremel, Gregory T. Bleck
-
Patent number: 6677500Abstract: The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality.Type: GrantFiled: August 15, 2001Date of Patent: January 13, 2004Assignee: Board of Trustees of the University of IllinoisInventors: Matthew B. Wheeler, Sharon M. Donovan, Gregory T. Bleck, Marcia Monaco-Seigel
-
Publication number: 20040003421Abstract: The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6′ position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy.Type: ApplicationFiled: January 23, 2003Publication date: January 1, 2004Applicant: Pharming B.V.Inventors: Arnold J.J. Reuser, Ans T. Van der Ploeg, Frank R. Pieper, Martin Ph. Verbeet
-
Publication number: 20030229908Abstract: An improved method of nuclear transfer involving the transplantation of differentiated donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation. Also, methods for improving nuclear transfer efficiency by genetically altering donor cells to inhibit apoptosis, select for a specific cell cycle and/or enhance embryonic growth and development are provided.Type: ApplicationFiled: December 27, 2002Publication date: December 11, 2003Applicant: Advanced Cell TechnologyInventors: Jose Cibelli, Michael D. West
-
Publication number: 20030229910Abstract: A method for generating cattle resistant to Bovine Spongioform Encephalopathy through targeted alterations in the PrP gene is disclosed. The PrP gene of a cultured cells is altered to prevent its translation or to encode a dominant disease-resistant form of the protein, and the nucleus of the altered cell is used to clone a founder animal. In one embodiment, a single-stranded DNA fragment containing the alteration is used in single-stranded short fragment homologous replacement to alter the PrP gene.Type: ApplicationFiled: April 17, 2003Publication date: December 11, 2003Inventors: Richard Metz, R. Michael Blaese
-
Publication number: 20030221200Abstract: A milk or other dairy product, capable of minimising the onset of disease such as coronary heart disease or enhancing the immune response is derived from animals which are substantially free of the &bgr;-casein A1 allele. Bulk milk can be produced by testing for and culling cows who test positive for the &bgr;-casein A1 allele, or by producing immunoglobulins and other immune response proteins, in cow's milk from animals not possessing the &bgr;-casein A1 allele, or other commercial milk producing animals, to this allele, to counteract the immnunosuppressant substances present that are produced from it, in commercial milking cows such as Holsteins, together with its blending with non-treated milk or the recovery of such immunoproteins.Type: ApplicationFiled: February 21, 2003Publication date: November 27, 2003Inventor: Corran Norman Stuart McLachlan
-
Publication number: 20030217374Abstract: This invention includes methods for producing non-human mammals expressing monoclonal or oligoclonal B or T lymphocytes, as well as embryonic and hematopoietic stem cells that differentiate into monoclonal or oligoclonal B or T cells, using cloning by nuclear transfer with a B or T cell of interest as the nuclear donor cell.Type: ApplicationFiled: January 15, 2003Publication date: November 20, 2003Applicant: Advanced Cell TechnologyInventor: Michael D. West